Related Experiment Video
Updated: Sep 20, 2025
Quantifying Cognitive Decrements Caused by Cranial Radiotherapy
Published on: October 18, 2011
Memantine in the Prevention of Radiation-Induced Brain Damage: A Narrative Review
Claudia Scampoli1, Silvia Cammelli1,2, Erika Galietta1
1Department of Experimental, Diagnostic and Specialty Medicine-DIMES, Alma Mater Studiorum University of Bologna, 40138 Bologna, Italy.
Abstract:
Preserving cognitive functions is a priority for most patients with brain metastases. Knowing the mechanisms of hyperglutamatergic neurotoxicity and the role of some hippocampal areas in cognitive decline (CD) led to testing both the antiglutamatergic pharmacological prophylaxis and hippocampal-sparing whole-brain radiotherapy (WBRT) techniques. These studies showed a relative reduction in CD four to six months after WBRT. However, the failure to achieve statistical significance in one study that tested memantine alone (RTOG 0614) led to widespread skepticism about this drug in the WBRT setting. Moreover, interest grew in the reasons for the strong patient dropout rates in the first few months after WBRT and for early CD onset. In fact, the latter can only partially be explained by subclinical tumor progression. An emerging interpretation of the (not only) cognitive impairment during and immediately after WBRT is the dysfunction of the limbic and hypothalamic system with its immune and hormonal consequences. This new understanding of WBRT-induced toxicity may represent the basis for further innovative trials. These studies should aim to: (i) evaluate in greater detail the cognitive effects and, more generally, the quality of life impairment during and immediately after WBRT; (ii) study the mechanisms producing these early effects; (iii) test in clinical studies, the modern and advanced WBRT techniques based on both hippocampal-sparing and hypothalamic-pituitary-sparing, currently evaluated only in planning studies; (iv) test new timings of antiglutamatergic drugs administration aimed at preventing not only late toxicity but also acute effects.
Insights
Preserving cognitive function after whole-brain radiotherapy (WBRT) is crucial. Studies show hippocampal-sparing WBRT reduces cognitive decline, but new research explores early toxicity mechanisms and advanced techniques for better patient outcomes.
Area of Science:
- Neuroscience
- Oncology
- Radiotherapy
Background:
- Cognitive decline is a major concern for brain metastasis patients undergoing whole-brain radiotherapy (WBRT).
- Hyperglutamatergic neurotoxicity and hippocampal function are implicated in cognitive decline (CD).
- Previous studies showed a relative reduction in CD with hippocampal-sparing WBRT, but memantine monotherapy (RTOG 0614) lacked statistical significance, causing skepticism.
Purpose of the Study:
- To investigate the mechanisms behind early cognitive impairment and high dropout rates following WBRT.
- To explore the role of limbic and hypothalamic system dysfunction in WBRT-induced toxicity.
- To propose future clinical trials focusing on advanced WBRT techniques and novel drug administration timings.
Main Methods:
- Review of existing studies on antiglutamatergic prophylaxis and hippocampal-sparing WBRT.
- Analysis of patient dropout rates and early cognitive decline onset.
- Emerging interpretation of WBRT toxicity involving limbic and hypothalamic systems.
Main Results:
- Hippocampal-sparing WBRT demonstrated a relative reduction in cognitive decline four to six months post-treatment.
- Memantine monotherapy failed to achieve statistical significance in preventing WBRT-induced cognitive decline.
- Early cognitive decline and patient dropout suggest mechanisms beyond subclinical tumor progression, potentially involving limbic/hypothalamic dysfunction.
Conclusions:
- WBRT-induced toxicity may involve limbic and hypothalamic system dysfunction, impacting cognitive and quality of life outcomes.
- Future trials should evaluate advanced WBRT techniques (hippocampal-sparing, hypothalamic-pituitary-sparing) and optimized antiglutamatergic drug timing.
- Further research is needed to fully understand and mitigate early WBRT-induced cognitive impairment.
More Related Videos
Related Concept Videos
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
01:14Antiepileptic Drugs: Glutamate Antagonists
01:22Alzheimer's Disease: Treatment